Blood Group Genotyping for Sickle Cell and Thalassaemia
key details
| Status | complete |
|---|---|
| Procedure | direct |
| OCID | ocds-h6vhtk-05f01d |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| NHSBT | £140,671 | 14 May 2025 | active |
description
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to commencing 25 June 2025 until 31 March 2026.
notice history
4 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 5 Dec 2025 | Transparency notice (UK5) | Procurement Act 2023 | 080318-2025 |
| 5 Dec 2025 | Contract award (UK6) | Procurement Act 2023 | 080350-2025 |
| 10 Jun 2026 | Contract details (UK7) | Procurement Act 2023 | 054590-2026 |
| 10 Jun 2026 | Contract termination (UK11) | Procurement Act 2023 | 054644-2026 |
more from NHS England
- Exam Support Packages for EoE GP Registrars · £72,673 · 24 Jul 2026
- Refer a Patient - Adult ECMO 2026/27 · £99,362 · 23 Jul 2026
- Higher Specialist Scientist Training Programme (HSST) · £42,186,231 · 23 Jul 2026
- Imaging National Lecture Series · £400,000 · 22 Jul 2026
- NHS National Framework for Lenvatinib · £35,833,000 · 22 Jul 2026
- The Practice Education Facilitator role in Return to Practice · £20,000 · 22 Jul 2026
- Pharmacy Technician Clinical Skills Development · £300,000 · 22 Jul 2026
- NHS National Framework for Ferric Carboxymaltose injection · £62,633,000 · 21 Jul 2026
all contracts from this buyer →
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.